TY - JOUR
T1 - Role of hs-CRP in Post-MI Sequelae
T2 - Insights into Mechanisms and Clinical Significance
AU - Trivedi, Yash Vardhan
AU - Munjal, Parth
AU - Singh, Bhupinder
AU - Kanwar, Rhea
AU - Gupta, Aachal
AU - Jain, Rohit
N1 - Publisher Copyright:
© 2025 by The Southern Medical Association.
PY - 2025/7/1
Y1 - 2025/7/1
N2 - High-sensitivity C-reactive protein (hs-CRP) is a key marker of inflammation, predominantly produced by hepatocytes and various tissues, including intracardiac tissue, atherosclerotic plaques, and vascular smooth muscles. The biomarker serves as a crucial element of innate immunity and rises in response to various disease processes, including infections and cancers. This rise is triggered by the release of cytokines, primarily interleukin-6, tumor necrosis factor, and interleukin-1β. The utility of hs-CRP in clinical practice is being further explored, particularly regarding its role in cardiovascular disease, a leading cause of morbidity and mortality globally. Studies have demonstrated that elevated hs-CRP levels are associated with an increased risk of myocardial infarction (MI) and other cardiovascular events. hs-CRP has been suggested to play a role in the development of atrial and ventricular arrhythmias post-MI, although further research is needed to fully clarify this relationship. hs-CRP has been proposed as a potential biomarker for the early detection of post-MI events and be used for cardiovascular disease risk stratification, categorizing individuals into low-, intermediate-, and high-risk groups. In this study, we discuss the role of hsCRP in predicting adverse outcomes in various cardiovascular conditions, highlighting its potential as a valuable biomarker in clinical practice.
AB - High-sensitivity C-reactive protein (hs-CRP) is a key marker of inflammation, predominantly produced by hepatocytes and various tissues, including intracardiac tissue, atherosclerotic plaques, and vascular smooth muscles. The biomarker serves as a crucial element of innate immunity and rises in response to various disease processes, including infections and cancers. This rise is triggered by the release of cytokines, primarily interleukin-6, tumor necrosis factor, and interleukin-1β. The utility of hs-CRP in clinical practice is being further explored, particularly regarding its role in cardiovascular disease, a leading cause of morbidity and mortality globally. Studies have demonstrated that elevated hs-CRP levels are associated with an increased risk of myocardial infarction (MI) and other cardiovascular events. hs-CRP has been suggested to play a role in the development of atrial and ventricular arrhythmias post-MI, although further research is needed to fully clarify this relationship. hs-CRP has been proposed as a potential biomarker for the early detection of post-MI events and be used for cardiovascular disease risk stratification, categorizing individuals into low-, intermediate-, and high-risk groups. In this study, we discuss the role of hsCRP in predicting adverse outcomes in various cardiovascular conditions, highlighting its potential as a valuable biomarker in clinical practice.
UR - https://www.scopus.com/pages/publications/105009991907
UR - https://www.scopus.com/pages/publications/105009991907#tab=citedBy
U2 - 10.14423/SMJ.0000000000001848
DO - 10.14423/SMJ.0000000000001848
M3 - Review article
C2 - 40663124
AN - SCOPUS:105009991907
SN - 0038-4348
VL - 118
SP - 382
EP - 386
JO - Southern Medical Journal
JF - Southern Medical Journal
IS - 7
ER -